12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RX-3117: Phase I data

Rexahn reported data from a European Phase I trial in 9 cancer patients showing that RX-3117 met the primary endpoint of determining oral bioavailability. Details were not disclosed. No...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >